Answers are grounded in this paper and cite their sources.
The clinical strategy for developing the SEM Scanner is noteworthy. SEM technology using anatomy-specific data enables HCPs to provide early PI prevention interventions before visible signs of tissue damage develop while the damage is still reversible. When adopted into routine practice, the device identifies an increased risk of developing PIs 5 days (median) earlier than STA. FDA clearance was based on bench studies and data from three foundational trials that demonstrate the diagnostic accuracy of the device algorithm significantly exceeding clinical judgment (p < 0.001).
No takes yet. Share an insight, caveat, or question.
Bryant et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: